Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

29.60 +3.33 (+12.68%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Harmony Biosciences Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Expert Ratings for Harmony Biosciences
 
Via Benzinga
ZYNERBA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Zynerba Pharmaceuticals, Inc. - ZYNE
From Kahn Swick & Foti, LLC
Via Business Wire
NASDAQ: HRMY Investor Alert: Investigation over Potential Wrongdoing at Harmony Biosciences Holdings, Inc.
San Diego, CA -- (SBWIRE) -- 08/17/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at Harmony Biosciences Holdings, Inc. 
Via SBWire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Zynerba Pharmaceuticals, Inc. (Nasdaq - ZYNE), Chindata Group Holdings Limited (Nasdaq - CD), Capri Holdings Limited (NYSE – CPRI), Avid® (Nasdaq - AVID)
From Brodsky & Smith LLC
Via GlobeNewswire
The Latest Analyst Ratings for Harmony Biosciences
 
Via Benzinga
Harmony Biosciences's Earnings Outlook
 
Via Benzinga
Crude Oil Down 1%; Zynerba Pharmaceuticals Shares Spike Higher
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining around 90 points on Monday. The Dow traded down 0.14% to 35,232.62 while the NASDAQ rose 0.66% to 13,735.42. The... 
Via Benzinga
Topics Stocks
Why Is Zynerba Pharmaceuticals (ZYNE) Stock Up 270% Today?
With Harmony Biosciences acquiring Zynerba Pharmaceuticals, ZYNE stock jumped on both the buyout and the underlying therapeutic implications. 
Via InvestorPlace
Health Care Company Harmony Biosciences Announces Acquisition of Zynerba Pharmaceuticals
 
Via Benzinga
A Look Into Healthcare Sector Value Stocks
 
Via Benzinga
Why Zynerba Pharmaceuticals Stock Is Skyrocketing Today?
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shares are skyrocketing Monday after Harmony Biosciences (NASDAQ: HRMY) announced it will 
Via Benzinga
Analyst Expectations for Harmony Biosciences's Future
 
Via Benzinga
Harmony Biosciences Earnings Perspective: Return On Capital Employed
 
Via Benzinga
Analyst Expectations for Harmony Biosciences's Future
 
Via Benzinga
Earnings Outlook For Harmony Biosciences
 
Via Benzinga
7 ‘Strong Buy’ Value Stocks You Should Be Loading Up On Now
Although ultra-cheap ideas tend to carry significant risks, these strong buy value stocks offer the endorsement of analysts. 
Via InvestorPlace
Harmony Biosciences (HRMY) Q2 2023 Earnings Call Transcript
HRMY earnings call for the period ending June 30, 2023. 
Via The Motley Fool
Harmony Biosciences Reports Second Quarter 2023 Financial Results and Business Updates
From Harmony Biosciences
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
7 Best High-Growth Stocks to Buy if You’re a Young Investor
If you’re just starting out and have plenty of time to work with, these are the high-growth stocks for young investors. 
Via InvestorPlace
Analyst Ratings for Harmony Biosciences
 
Via Benzinga
3 Biotech Stocks to Buy With Explosive Upside Potential
These three biotech stocks with high upside potential also display some significant risk, but less so than many of their small-cap peers. 
Via InvestorPlace
Bragar Eagel & Squire, P.C. Is Investigating Techtronic, Boxed, Coinbase, and Harmony and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Harmony Biosciences (HRMY) Q1 2023 Earnings Call Transcript
HRMY earnings call for the period ending March 31, 2023. 
Via The Motley Fool
Harmony Biosciences Reports First Quarter 2023 Financial Results and Business Updates
From Harmony Biosciences
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating LivePerson, and Harmony and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2023
 
Via Benzinga
7 Stocks to Buy to Bag Big-Time Returns in Q2
If you’re willing to take huge risks, these stocks to buy might yield you massive gains in Q2 – or you could be looking at a tax write-off. 
Via InvestorPlace
NASDAQ:HRMY Shareholder Alert: Investigation over Possible Securities Laws Violations by Harmony Biosciences Holdings, Inc.
San Diego, CA -- (SBWIRE) -- 04/14/2023 -- An investigation was announced for investors of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) shares over potential securities laws violations by Harmony... 
Via SBWire
Bragar Eagel & Squire, P.C. Is Investigating LivePerson, and Harmony and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.